Bharat Edition

Bharatstox

← All stocks

Anupam Rasayan India Ltd.

NSE: ANURAS · Chemicals

Sector

Chemicals

Size band

Small cap

Market cap

14,143cr

P/E

90

ROE

2.7%

Dividend yield

0.1%

No price is shown on this page, live or delayed. It records what management said on the earnings call, and the company’s filings.

Measured against

Operating margin25.0%
peer 19.0%
Revenue growth34.8%
peer 27.4%
Anupam Rasayan India Ltd.peer median

Peer set

Speciality Chemicals · largest 12 of 32 measured at Q1 FY27 · financials via Screener
CompanyOperating marginRevenue growth
Gujarat Fluorochemicals Ltd.27.0%24.0%
Navin Fluorine International Ltd.34.0%44.1%
Atul Ltd.21.0%25.0%
Aarti Industries Ltd.16.0%42.5%
Aether Industries Ltd.31.0%27.2%
Anupam Rasayan India Ltd.25.0%34.8%
Vinati Organics Ltd.24.0%28.4%
Privi Speciality Chemicals Ltd.23.0%19.1%
Jubilant Ingrevia Ltd.15.0%25.2%
Clean Science And Technology Ltd.36.0%10.3%
Alkyl Amines Chemicals Ltd.25.0%30.0%
Epigral Ltd.25.0%16.1%

What management said

8 statements on record

Earnings call · Q1 FY27 / quarter ended June 30, 2026 · 20 Aug 2026

  • Consolidated EBITDA margin22% to 24% EBITDA margin· next 2 to 3 years
    And on a consol basis, we should be looking at anything between 22% to 24% EBITDA margin is what I would really guide at because there are multiple companies, multiple segments, multiple end markets.
  • Standalone EBITDA margin24% to 26%· next 2 to 3 years
    So typically, as I have been always guiding that on a standalone, we should be looking at anything between 24% to 26% on a standalone basis.
  • Polymer business contribution20% to 25% standalone; 30% to 35% consolidated
    But we believe that on a standalone, we should be able to get a polymer business to be in the range of 20% to 25%. And on a consolidated basis, it should be in the range of 30% to 35%.
  • CapexINR70 crores to INR80 crores· FY27 and FY28 / for now
    And to my mind, in the range of INR70 crores to INR80 crores may be the number that I would look at from a capex point of view, for now.
  • Revenue growth25 plus or minus a couple of percentage points organic; another 10% to 15% additional growth from Jayhawk· FY27
    So if you see, what we had also mentioned earlier in our call and this also, we believe that the number will continue to be in the range of 25 plus or minus a couple of percentage points in terms of our revenue growth on an organic basis. And with the addition of the Jayhawk, that number will be added because Jayhawk was not counted in our last year's revenue, any significant revenue. So another 10% to 15% of additional growth will come because of the addition of Jayhawk's revenue line.
  • Order book revenue contribution25% of revenue this year; around 30% going forward· this year and going forward
    This year, we are expecting it to be significantly higher, contributing around about 25% of our revenue. And going forward, it should contribute around 30%-odd of our revenue with the higher base volume that we have.
  • Bliss GVS capacity utilisation60% to 70%· next 2 to 3 years
    So we continue to believe that we should be able to improve the utilization of the company's assets to 60% to 70%, and that would translate to the kind of numbers that are there, that would be there.
  • Debt for Bliss acquisitionaround about INR300 crores
    There, we will be taking a debt of around about INR300 crores.

Taken from management commentary on the company’s earnings call and quoted verbatim. These are statements of intent made by the company, not forecasts by Bharatstox, and nothing here records whether they were met.

On air

1 call · outcomes not tracked

Recorded as stated on air, with the analyst's SEBI registration status where it was given. Anchor calls carry no registration and are marked. Bharatstox does not make, endorse or repeat these calls, and none of them is our view.

Channel & showAiredStated targetStated stopOutcome
NDTV ProfitNDTV Profit · no registration attached19 Aug+11.2%still open

Shareholding

change across 4 filings
CategoryJun 26Mar 26Dec 25Sep 25Change
Promoters59.159.159.159.10.0
Foreign institutions7.76.97.67.6+0.1
Domestic institutions0.40.40.41.4−1.0
Retail & others32.833.732.931.9+0.9

As filed with the exchange for the periods ending Sep 25 to Jun 26.

Filings

latest 25 of 218
  • General Updates7 Sept 2026
    High impactM&AFiling PDF ↗
  • The Board of Directors of the Company at its meeting held on September 07, 2026, has approved the acquisition of equity shares in Tanfac Industries Limited pursuant to a preferential issue.7 Sept 2026
    High impactM&AFiling PDF ↗
  • Appointment7 Sept 2026
    Medium impactAppointmentFiling PDF ↗
  • The Board of Directors of the Company at its meeting held on September 07, 2026, has considered and approved the appointment of Ms. Hetvi Vyas as Chief Deputy Financial Officer and Key ....7 Sept 2026
    Medium impactAppointmentFiling PDF ↗
  • Record Date7 Sept 2026
    Medium impactDividendFiling PDF ↗
  • The Board of Directors of the Company at its meeting held on September 07, 2026, has approved and fixed the record date as Friday, September 18, 2026, for the payment of final dividend ....7 Sept 2026
    RoutineBoard MeetingFiling PDF ↗
  • Outcome of Board Meeting7 Sept 2026
    RoutineBoard MeetingFiling PDF ↗
  • Outcome of Board Meeting held on September 07, 2026.7 Sept 2026
    RoutineBoard MeetingFiling PDF ↗
  • Copy of Newspaper Publication1 Sept 2026
    RoutineGeneralFiling PDF ↗
  • Submission of Newspaper Advertisement clippings pertaining to Post Offer Advertisement.1 Sept 2026
    RoutineGeneralFiling PDF ↗
  • Credit Rating31 Aug 2026
    Medium impactCredit RatingFiling PDF ↗
  • The credit rating agency Crisil Ratings Limited has continued its ratings on the bank facilities and non-convertible debentures of the Company.31 Aug 2026
    High impactFundraiseFiling PDF ↗
  • Analysts/Institutional Investor Meet/Con. Call Updates20 Aug 2026
    RoutineResultsFiling PDF ↗
  • Submission of transcript of earnings call on the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026.20 Aug 2026
    RoutineResultsFiling PDF ↗
  • Analysts/Institutional Investor Meet/Con. Call Updates14 Aug 2026
    RoutineResultsFiling PDF ↗
  • Investor Presentation14 Aug 2026
    RoutineGeneralFiling PDF ↗
  • Press Release14 Aug 2026
    RoutineResultsFiling PDF ↗
  • Appointment14 Aug 2026
    Medium impactAppointmentFiling PDF ↗
  • Outcome of Board Meeting14 Aug 2026
    RoutineBoard MeetingFiling PDF ↗
  • ESOP/ESOS/ESPS13 Aug 2026
    RoutineGeneralFiling PDF ↗
  • Analysts/Institutional Investor Meet/Con. Call Updates11 Aug 2026
    RoutineResultsFiling PDF ↗
  • Copy of Newspaper Publication27 Jul 2026
    RoutineGeneralFiling PDF ↗
  • General Updates21 Jul 2026
    High impactM&AFiling PDF ↗
  • Submission of Letter of Offer regarding the open offer for acquisition of fully paid-up equity shares of Bliss GVS Pharma Limited from the Public Shareholders, by the Company together with PAC21 Jul 2026
    High impactM&AFiling PDF ↗
  • General Updates17 Jul 2026
    High impactM&AFiling PDF ↗

The 25 most recent of 218 filings we hold for ANURAS, back to January 2024. Every filing, by day.

Disclaimer

Guidance is quoted from management commentary on quarterly earnings calls; the words are the company's own and the targets are theirs, not ours. Peer comparisons use quarterly financials sourced from Screener, with every company measured at the same fiscal quarter; the peer set is companies sharing the same industry classification, and comparisons are descriptive, not a ranking or a view. Broadcast calls are reproduced as stated on air, attributed, with the analyst's SEBI registration status where given; they are not our calls and not our view. Filings are reproduced as companies filed them to the NSE and BSE; Bharatstox does not verify, endorse or comment on their contents. This page is for informational and educational purposes only and does not constitute investment advice, research, or a recommendation to buy or sell any security. Investing in securities markets is subject to market risks. Read all related documents carefully before investing.

Bharat ke stocks, har subah.

One daily brief on what India's SEBI-registered research analysts are calling. No noise, no spam, unsubscribe whenever.